In 2007, the US Food and Drug Administration issued a safety alert about the possible association between the diabetes drug rosiglitazone and increased risk of heart problems, and in 2009 ordered its maker, GlaxoSmithKline, to conduct a clinical trial. Image courtesy of Reuters/Toby Melville